Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Lilly

Status and phase

Completed

Phase 4

Conditions

Attention Deficit Hyperactivity Disorder

Comorbid Social Anxiety Disorder

Treatments

Drug: Atomoxetine hydrochloride

Drug: placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00190879

B4Z-US-LYDQ

9855

Details and patient eligibility

About

To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

You must be 18 to 65 years old.
You must have been diagnosed with attention deficit hyperactivity disorder and social anxiety disorder.
You must be able to visit the doctor's office at least 8 times over a 16 week period.
You must agree to participate with all tests and examinations that are required for this study.

Exclusion criteria

You are a woman and pregnant or breastfeeding.
You presently have an acute or unstable medical illness.
You have a history of allergic reaction to atomoxetine hydrochloride.
You are taking medications that are not permitted in this study. Your physician will discuss these with you.
You have taken part in another clinical research trial within the last 30 days or have received treatment with a drug in the last 30 days that has not received regulatory approval.